Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men
- 1 November 2019
- journal article
- conference paper
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 82 (3) , 252-256
Abstract
Background: Urine provides a minimally invasive specimen that may allow for development of rapid tests to detect antiretroviral drugs and provide opportunities to improve individual adherence. This study sought to determine whether urine could provide a biomarker of adherence for currently approved pre-exposure prophylaxis and HIV treatment regimens. Methods: Urine and blood were collected from 34 HIV-negative men who have sex with men aged 18–49 years, enrolled in a clinical trial comparing 2 antiretroviral regimens. Specimens were collected 4 and 24 hours after a single oral dose of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) (n = 10) or tenofovir alafenamide (TAF)/FTC/cobicistat (COBI)/elvitegravir (EVG) (n = 8), or after 4 and 10 days of daily oral TDF/FTC (n = 9) or TAF/FTC/COBI/EVG (n = 7). Tenofovir (TFV), FTC, and EVG were measured by high-performance liquid chromatography-mass spectrometry. Results: Median urine FTC concentrations at 4 and 24 hours were similar between men receiving TDF/FTC (4 hours 147 µg/mL; 24 hours 10 µg/mL) and men receiving TAF/FTC/COBI/EVG (4 hours 333 µg/mL, P = 0.173; 24 hours 13 µg/mL, P = 0.681). Median urine TFV concentrations were lower among men receiving TAF/FTC/COBI/EVG (4 hours 1.2 µg/mL; 24 hours 0.8 µg/mL) compared with men receiving TDF/FTC (4 hours 17 µg/mL, P < 0.001; 24 hours 7 µg/mL, P = 0.001). Urine TFV concentrations remained reduced among men receiving TAF/FTC/COBI/EVG compared with men receiving TDF/FTC after daily dosing. EVG was not consistently measurable in urine. Conclusions: High urine FTC and TFV concentrations could provide an indication of adherence to daily oral dosing with TDF or TAF-based regimens used for treatment and prevention.Keywords
This publication has 35 references indexed in Scilit:
- Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive AdultsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- A validated assay by liquid chromatography–tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patientsJournal of Mass Spectrometry, 2013
- Tenofovir, Emtricitabine, and Tenofovir Diphosphate in Dried Blood Spots for Determining Recent and Cumulative Drug ExposureAIDS Research and Human Retroviruses, 2013
- Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and WomenNew England Journal of Medicine, 2012
- Multiple Measures Reveal Antiretroviral Adherence Successes and Challenges in HIV-Infected Ugandan ChildrenPLOS ONE, 2012
- Assessing the association between self-report items for HIV pill adherence and biological measuresAIDS Care, 2012
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyNew England Journal of Medicine, 2011
- Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor ElvitegravirClinical Pharmacokinetics, 2011
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010
- On-line coupling of anion exchange and ion-pair chromatography for measurement of intracellular triphosphate metabolites of reverse transcriptase inhibitorsJournal of Chromatography B, 2009